By JOHN SAMARAS
A US retail pharmacy pays $1,302 to acquire one month of branded Wegovy. That figure comes from the Centers for Medicare and Medicaid Services National Average Drug Acquisition Cost file, effective August 19, 2026, for the 25 mg oral tablet at 30 tablets a month.
The cheapest cash price I verified on a seller’s own published page, for the same month of the same product, is $299. That is oral Wegovy at the maintenance dose, at Sam’s Club Member Health, which sells at the manufacturer’s published self-pay price, checked August 31, 2026.
The two numbers are more than a thousand dollars apart.
Where the second number comes from
Every Monday I check what each US GLP-1 telehealth program publishes as its price, on the program’s own page, and record it. Not the advertised starting rate. Not the prepaid annual plan divided by twelve. The all-in monthly cost of staying on the drug at a maintenance dose.
This month that record turned into an index. Across a fixed panel of 11 programs the median all-in price was $348 a month in August, the same figure in all five weekly checks. It did not move against July.
One program cut its price in August and none raised one. GoodRx for Weight Loss went from $388 to $338 on August 31, and it sits outside the panel. Three other apparent cuts in the record were mine rather than the programs’. Ivim Health and Sesame Care were sitting on prepaid plan rates, and my Costco through Sesame row was carrying $408 for a plan that was $398 all month. Putting each on the rate a reader can start on today lands in the series as a step. The revision log on the September release itemizes all three. The cheapest verified compounded semaglutide route held at $178 a month, at Mochi Health, which posts one flat all-in price at every dose. Sam’s Club Member Health was the cheapest verified branded route at $299 for the Wegovy pill. Both figures were checked on August 31, 2026.
The method fits in a paragraph. For the floors, take the lowest published all-in price in each route on every Monday of the month, then take the median of those weekly lows. For the median, take the middle of the fixed panel each Monday, then the median of those five weekly figures. The panel is fixed on purpose, so a change in which programs I track cannot read as a change in price. The number sits at a dated URL and does not change after publication. A correction becomes a numbered revision with a note.
NADAC measures acquisition cost
The distance between $1,302 and $299 is not pharmacy margin. NADAC measures what pharmacies pay their wholesaler. It says nothing about dispensing costs, the clinician visit, shipping, or what a manufacturer charges through a channel it owns.
46brooklyn Research has published NADAC dashboards free since 2019, and every derivative here rests on their work. What I added is the join: their acquisition data against verified consumer cash prices, which nobody had put side by side.
The two prices sit in different channels. Insurance routes a patient into the pharmacy channel, where the $1,302 sits. The $299 is a cash price, paid by a buyer with no coverage.
The packaging gap
The same NADAC file holds a second finding. Lilly sells Zepbound both as single-dose pens and as a multi-dose KwikPen. At 15 mg, a pharmacy pays $672 a month for the KwikPen and $1,051 a month for the equivalent single-dose pens. The only difference is the container. The spread is 1.56x, or $379 a month. At the 2.5 mg starting dose it is $482 against $1,052, or 2.18x.
Why nobody else has this number
Prices in this category move weekly and nobody records them. A patient cannot tell an introductory rate from a maintenance rate. A reporter covering a price cut has no baseline to say whether it was a cut at all, and the only public numbers are the ones a manufacturer put in a press release.
The fix is somebody writing the price down every week and publishing the method with a version number on it.
Everything above is free to reuse under CC BY 4.0, with a link and no registration. The CSV and the JSON sit at https://glpchart.com/price-index/. If you want a different cut, by state, by drug or by program, ask and you will have it inside a day.
From October the release lands on the first Tuesday of the month. The next one is October 6, 2026.
John Samaras is the founder of GLP Chart, which verifies the cash price of every US GLP-1 telehealth program every Monday. He writes about price, coverage and market structure, and leaves the clinical questions to clinicians.
